NTRROTCMedicinal Chemicals & Botanical ProductsFiscal year ends January 31
NEUTRA CORP.
Financials through Q3 FY2024, quarter ended Oct 31, 2023Last filing: 10-Q on Aug 7, 2024
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2023
Gross margin
51.9%
Operating margin
-437.8%
Net margin
-825.7%
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -26.1% | +119.9% | – | – | |
| Gross profit | +13.3% | +76.7% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Return on equity | 326.8% | 72.1% | 54.9% | |
| Return on assets | -4690.6% | -8422.4% | -544.8% | |
| Current ratio | 0.14 | 0.02 | 0.03 | |
| Interest coverage | -3.3× | -0.5× | -4.8× | |
| Capex to revenue | – | – | – | |
| Diluted shares | 0M | 5M | – |
Cash use needs five years of cash flow figures
Neutra does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-825.7%
×Asset turnover0.66×
×Equity multiplier-0.10×
=Return on equity, FY202354.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -825.7% | 0.66× | -0.10× | 54.9% |
| FY2022 | -687.9% | 0.57× | -0.14× | 56.5% |
| FY2021 | -5563.0% | 0.05× | -0.21× | 59.3% |
| FY2020 | -10877.6% | 0.04× | -0.18× | 71.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
4of 7 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero-$561.42K
- Cash generatingOperating cash flow above zero-$153.24K
- Return on assets improvedROA up on the prior year-331.8% → -428.8%
- Earnings backed by cashOperating cash flow above net income-$153.24K vs -$561.42K
- Less leverageLong-term debt to assets fell– → 72.0%
- Better liquidityCurrent ratio rose0.00 → 0.03
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year33.87% → 51.92%
- More efficientAsset turnover rose0.48 → 0.52